Cairo - Mubasher: Minapharm Pharmaceuticals generated consolidated net profits after tax of EGP 61.81 million in the first nine months (9M) of 2025, lower year-on-year (YoY) than EGP 73.16 million.

The basic and diluted earnings per share (EPS) decreased to EGP 3.42 in 9M-25 from EGP 4.88 in the same period of 2024, according to the financial results.

Consolidated revenues totaled EGP 4.84 billion in 9M-25, signaling a YoY hike from EGP 3.58 billion.

During the January-September 2025 period, the consolidated total assets surged to EGP 13.37 billion from EGP 12 billion as of 31 December 2024.

Financial Statements for Q3

In the third quarter (Q3) of 2025, Minapharm registered an annual plunge in consolidated net profits after tax to EGP 15 million, against EGP 121.68 million.

Furthermore, the consolidated revenues went down to EGP 1.50 billion in Q3-25 from EGP 1.51 billion in Q3-24, whereas the basic and diluted EPS shrank to EGP 1.01 from EGP 11.89.

As for the standalone results, Minapharm logged net profits after tax worth EGP 66.56 million in 9M-25, compared to EGP 17.13 million in 9M-24.